Details for New Drug Application (NDA): 074703
NDA 074703 describes METOCLOPRAMIDE HYDROCHLORIDE, which is a drug marketed by Baxter Hlthcare Corp, Bedford, Fresenius Kabi Usa, Hospira, Lyphomed, Norbrook, Smith And Nephew, Teva Pharms Usa, Actavis Mid Atlantic, Ani Pharms, Chartwell Molecular, Morton Grove, Paco, Pai Holdings, Pharmobedient Cnsltg, Roxane, Teva, Vistapharm Llc, Novel Labs Inc, Aiping Pharm Inc, Chartwell Rx, Clonmel, Halsey, Impax Labs Inc, Interpharm, Ipca Labs Ltd, Mutual Pharm, Northstar Hlthcare, Par Pharm, Sandoz, Schering, Strides Pharma Intl, Sun Pharm Industries, Superpharm, Usl Pharma, and Watson Labs, and is included in fifty-four NDAs. It is available from thirty-six suppliers. Additional details are available on the METOCLOPRAMIDE HYDROCHLORIDE profile page.
The generic ingredient in METOCLOPRAMIDE HYDROCHLORIDE is metoclopramide hydrochloride. There is one drug master file entry for this compound. Forty suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.
The generic ingredient in METOCLOPRAMIDE HYDROCHLORIDE is metoclopramide hydrochloride. There is one drug master file entry for this compound. Forty suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.
Summary for 074703
| Tradename: | METOCLOPRAMIDE HYDROCHLORIDE |
| Applicant: | Pharmobedient Cnsltg |
| Ingredient: | metoclopramide hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 074703
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | EQ 5MG BASE/5ML | ||||
| Approval Date: | Oct 31, 1997 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
